Karyopharm Therapeutics | KPTI - Ebit


Karyopharm Therapeutics reported $-17.84M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Abbott USD 1.85B 684M Mar/2026
Amgen USD 3.83B 130M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Bristol-Myers Squibb USD 3.56B 90M Mar/2026
Eli Lilly USD 9.78B 792M Mar/2026
Enanta Pharmaceuticals USD -23.54M 6.31M Dec/2024
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Incyte USD 344.17M 39.71M Mar/2026
J&J USD 6.62B 1.51B Mar/2026
Karyopharm Therapeutics USD -17.84M 8.44M Dec/2025
MacroGenics USD -31.88M 19.79M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Novartis USD 4.18B 118M Mar/2026
Novartis USD 4.18B 118M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 2.1B Dec/2025
Takeda JPY -13.62B 271.11B Mar/2026
Tectonic Therapeutic USD -27.3M 5.78M Mar/2026
TG Therapeutics USD 34.8M 15.7M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Xencor USD -77.86M 24.23M Mar/2026